Autosomal dominant tubulointerstitial kidney disease: Diagnosis, classification, and management - A KDIGO consensus report

Kidney International

Volumn 88, Issue 4, 2015, Pages 676-683

  Eckardt, Kai Uwe ^a   Alper, Seth L ^b   Antignac, Corinne ^c,d   Bleyer, Anthony J ^e   Chauveau, Dominique ^f   Dahan, Karin ^g   Deltas, Constantinos ^h   Hosking, Andrew ⁱ   Kmoch, Stanislav ^j   Rampoldi, Luca ^k   Wiesener, Michael ^a   Wolf, Matthias T ^l   Devuyst, Olivier ^m  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c IMAGINE INSTITUTE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f CHU RANGUEIL   (France)

^g INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

^h UNIVERSITY OF CYPRUS   (Cyprus)

ⁱ UKD Foundation   (United States)

^j Charles University in Prague and General University Hospital in Prague   (Czech Republic)

^k DULBECCO TELETHON INSTITUTE   (Italy)

^l UNIVERSITY OF TEXAS AT DALLAS   (United States)

^m UNIVERSITY OF ZURICH   (Switzerland)

more..

Author keywords

genetics; hepatocyte nuclear factor 1 ; kidney disease; mucin 1; renin; uromodulin

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1BETA; MUCIN 1; PREPRORENIN; RENIN; TAMM HORSFALL GLYCOPROTEIN;

ARTICLE; AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DISORDER; GENETIC SCREENING; GLOMERULUS FILTRATION RATE; HNF1B GENE; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MEDICAL TERMINOLOGY; MEDICATION THERAPY MANAGEMENT; MUC1 GENE; NEPHRONOPHTHISIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REN GENE; TREATMENT CONTRAINDICATION; UMOD GENE; CLASSIFICATION; CONSENSUS; CONSENSUS DEVELOPMENT; DEFICIENCY; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; GOUT; HYPERURICEMIA; KIDNEY DISEASES; MUTATION; NEPHROLOGY; NOMENCLATURE; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PRACTICE GUIDELINE; PREDICTIVE VALUE; STANDARDS; TREATMENT OUTCOME;

CONSENSUS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GOUT; HUMANS; HYPERURICEMIA; KIDNEY DISEASES; MUTATION; NEPHROLOGY; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREDICTIVE VALUE OF TESTS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME; UROMODULIN;

EID: 84942986418     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.28     Document Type: Article

References (61)

1. Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169.
2. Titze S, Schmid M, Kottgen A et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 2014; pii: gfu294.
3. Devuyst O, Knoers NV, Remuzzi G et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014; 383: 1844-1859.
4. Freedman BI, Volkova NV, Satko SG et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 2005; 25: 529-535.
5. Torres VE, Harris PC. Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy. Nat Rev Nephrol 2012; 8: 66-68.
6. Bennett WM, Simon N, Gardner KD Jr. Cystic disease of renal medulla. Ann Intern Med 1971; 74: 1011-1012.
7. Christodoulou K, Tsingis M, Stavrou C et al. Chromosome 1 localization of a gene for autosomal dominant medullary cystic kidney disease. Hum Mol Genet 1998; 7: 905-911.
8. Dahan K, Fuchshuber A, Adamis S et al. Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: two facets of the same disease? J Am Soc Nephrol 2001; 12: 2348-2357.
9. Gardner KD Jr. Evolution of clinical signs in adult-onset cystic disease of the renal medulla. Ann Intern Med 1971; 74: 47-54.
10. Massari PU, Hsu CH, Barnes RV et al. Familial hyperuricemia and renal disease. Arch Intern Med 1980; 140: 680-684.
11. Parvari R, Shnaider A, Basok A et al. Clinical and genetic characterization of an autosomal dominant nephropathy. Am J Med Genet 2001; 99: 204-209.
12. Scolari F, Ghiggeri GM, Casari G et al. Autosomal dominant medullary cystic disease: A disorder with variable clinical pictures and exclusion of linkage with the NPH1 locus. Nephrol Dial Transplant 1998; 13: 2536-2546.
13. Smith CH, Graham JB. Congenital medullary cysts of the kidneys with severe refractory anemia. Am J Dis Child 1945; 69: 369-377.
14. Stavrou C, Koptides M, Tombazos C et al. Autosomal-dominant medullary cystic kidney disease type 1: clinical and molecular findings in six large Cypriot families. Kidney Int 2002; 62: 1385-1394.
15. Thompson GR, Weiss JJ, Goldman RT et al. Familial occurrence of hyperuricemia, gout, and medullary cystic disease. Arch Intern Med 1978; 138: 1614-1617.
16. Dahan K, Devuyst O, Smaers M et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 2003; 14: 2883-2893.
17. Hart TC, Gorry MC, Hart PS et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39: 882-892.
18. Rampoldi L, Caridi G, Santon D et al. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 2003; 12: 3369-3384.
19. Turner JJ, Stacey JM, Harding B et al. Uromodulin mutations cause familial juvenile hyperuricemic nephropathy. J Clin Endocrinol Metab 2003; 88: 1398-1401.
20. Wolf MT, Mucha BE, Attanasio M et al. Mutations of the Uromodulin gene in MCKD type 2 patients cluster in exon 4, which encodes three EGF-like domains. Kidney Int 2003; 64: 1580-1587.
21. Zivna M, Hulkova H, Matignon M et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. Am J Hum Genet 2009; 85: 204-213.
22. Lindner TH, Njolstad PR, Horikawa Y et al. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet 1999; 8: 2001-2008.
23. Kirby A, Gnirke A, Jaffe DB et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat Genet 2013; 45: 299-303.
24. Faguer S, Decramer S, Chassaing N et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int 2011; 80: 768-776.
25. Heidet L, Decramer S, Pawtowski A et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin J Am Soc Nephrol 2010; 5: 1079-1090.
26. Bleyer AJ, Kmoch S, Antignac C et al. Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol 2014; 9: 527-535.
27. Bollee G, Dahan K, Flamant M et al. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clin J Am Soc Nephrol 2011; 6: 2429-2438.
28. Ekici AB, Hackenbeck T, Moriniere V et al. Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin. Kidney Int 2014; 86: 589-599.
29. Bleyer AJ, Hart PS, Kmoch S. Hereditary interstitial kidney disease. Semin Nephrol 2010; 30: 366-373.
30. Bleyer AJ, Kmoch S. Autosomal dominant tubulointerstitial kidney disease: of names and genes. Kidney Int 2014; 86: 459-461.
31. Bleyer AJ, Zivna M, Kmoch S. Uromodulin-associated kidney disease. Nephron Clin Pract 2011; 118: c31-c36.
32. Rampoldi L, Scolari F, Amoroso A et al. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 2011; 80: 338-347.
33. Moskowitz JL, Piret SE, Lhotta K et al. Association between genotype and phenotype in uromodulin-associated kidney disease. Clin J Am Soc Nephrol 2013; 8: 1349-1357.
34. Hoefele J, Nayir A, Chaki M et al. Pseudodominant inheritance of nephronophthisis caused by a homozygous NPHP1 deletion. Pediatr Nephrol 2011; 26: 967-971.
35. Lens XM, Banet JF, Outeda P et al. A novel pattern of mutation in uromodulin disorders: Autosomal dominant medullary cystic kidney disease type 2, familial juvenile hyperuricemic nephropathy, and autosomal dominant glomerulocystic kidney disease. Am J Kidney Dis 2005; 46: 52-57.
36. Nasr SH, Lucia JP, Galgano SJ et al. Uromodulin storage disease. Kidney Int 2008; 73: 971-976.
37. Wilcox WD. Abnormal serum uric acid levels in children. J Pediatr 1996; 128: 731-741.
38. Kurt B, Paliege A, Willam C et al. Deletion of von Hippel-Lindau protein converts renin-producing cells into erythropoietin-producing cells. J Am Soc Nephrol 2013; 24: 433-444.
39. Faguer S, Chassaing N, Bandin F et al. The HNF1B score is a simple tool to select patients for HNF1B gene analysis. Kidney Int 2014; 86: 1007-1015.
40. Bernascone I, Janas S, Ikehata M et al. A transgenic mouse model for uromodulin-associated kidney diseases shows specific tubulo-interstitial damage, urinary concentrating defect and renal failure. Hum Mol Genet 2010; 19: 2998-3010.
41. Bernascone I, Vavassori S, Di Pentima A et al. Defective intracellular trafficking of uromodulin mutant isoforms. Traffic 2006; 7: 1567-1579.
42. Mutig K, Kahl T, Saritas T et al. Activation of the bumetanide-sensitive Na, K, 2Cl-cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner. J Biol Chem 2011; 286: 30200-30210.
43. Scolari F, Caridi G, Rampoldi L et al. Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 2004; 44: 987-999.
44. Kraus S, Abel PD, Nachtmann C et al. MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol 2002; 33: 60-67.
45. Leroy X, Zerimech F, Zini L et al. MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 2002; 118: 47-51.
46. Coffinier C, Barra J, Babinet C et al. Expression of the vHNF1/HNF1beta homeoprotein gene during mouse organogenesis. Mech Dev 1999; 89: 211-213.
47. Kolatsi-Joannou M, Bingham C, Ellard S et al. Hepatocyte nuclear factor-1beta: A new kindred with renal cysts and diabetes and gene expression in normal human development. J Am Soc Nephrol 2001; 12: 2175-2180.
48. Gresh L, Fischer E, Reimann A et al. A transcriptional network in polycystic kidney disease. EMBO J 2004; 23: 1657-1668.
49. Prieto MC, Gonzalez AA, Navar LG. Evolving concepts on regulation and function of renin in distal nephron. Pflugers Arch 2013; 465: 121-132.
50. Prieto MC, Das S, Somanna NK et al. Disruption of Npr1 gene differentially regulates the juxtaglomerular and distal tubular renin levels in null mutant mice. Int J Physiol Pathophysiol Pharmacol 2012; 4: 128-139.
51. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
52. Dang A, Zhang Y, Liu G et al. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens 2006; 20: 45-50.
53. Hamada T, Ichida K, Hosoyamada M et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21: 1157-1162.
54. McDonagh EM, Thorn CF, Callaghan JT et al. PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics 2014; 24: 464-476.
55. Faruque LI, Ehteshami-Afshar A, Wiebe N et al. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 2013; 43: 367-375.
56. Labriola L, Olinger E, Belge H et al. Paradoxical response to furosemide in uromodulin-associated kidney disease. Nephrol Dial Transplant 2015; 30: 330-335.
57. Bleyer AJ, Zivna M, Hulkova H et al. Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone. Clin Nephrol 2010; 74: 411-422.
58. Stavrou C, Deltas CC, Christophides TC et al. Outcome of kidney transplantation in autosomal dominant medullary cystic kidney disease type 1. Nephrol Dial Transplant 2003; 18: 2165-2169.
59. Kottgen A, Glazer NL, Dehghan A et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009; 41: 712-717.
60. Trudu M, Janas S, Lanzani C et al. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med 2013; 19: 1655-1660.
61. Beck BB, Trachtman H, Gitman M et al. Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD. Am J Kidney Dis 2011; 58: 821-825.